Imaging technology is required to enable personalised adaptation of treatment for improved outcomes for patients with soft-tissue sarcoma, specifically techniques which can identify those patients who would benefit from neoadjuvant therapy prior to surgery, accurately assess tumour response, and enable expedient switching to a more efficacious agent/treatment regime as necessary. The objective of this project is to use advanced, clinicallytranslatable multi-parametric MRI strategies, coupled with computational pathology, to define imaging biomarkers associated with the heterogeneous phenotype that develops within patient-derived xenograft models of soft-tissue sarcoma, and for the assessment of tumour response to neoadjuvant therapy.